What are the chances we presently have of carrying a cardiovascular disease at some point in our lives?

Original title: Lifetime Risk and Years Lived Free of Total Cardiovascular Disease Reference: John T. Wilkins et al. JAMA. 2012; 308(17):1795-1801.

This study analyzed more than 120,000 patients in the cohorts of large community studies, such as the Framingham, who did not have cardiovascular disease at the time of inclusion 

Considering all the age subgroups, only between 1.7% and 7.9% were within the optimal range of risk factors, (BP <120/80 mmHg, total cholesterol

In contrast, more than 55% of the population had one or two risk factors analyzed whatever their age. With this data it was possible to calculate, for example, that a 45 year-old man with no history has a 60.3% risk of contracting a cardiovascular disease at some point in his life.

For a woman of the same age the risk factor is 55.6%. In a middle age, a person with optimal risk control factors has an estimated 14 more years of free cardiovascular disease than someone of the same age with 2 risk factors. However, despite the likelihood of optimal control of risk, the odds of contracting an illness are still above 30%.

Editorial Comment: 

This study shows the enormous prevalence of cardiovascular disease and that this will continue to rise beyond the level that medical treatment can manage. Dealing with this huge number of patients is not only going to be a challenge for us in the catheterization laboratory but also an enormous public health problem.

SOLACI.ORG

More articles by this author

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....